[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transcutaneous-vagal-nerve-stimulation-tvns\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transcutaneous-vagal-nerve-stimulation-tvns":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100603067","the-effect-of-transcutaneous-vagal-nerve-stimulation-tvns-on-cerebral-vasospasm-secondary-to-aneurysmal-subarachnoid-hemorrhage-100603067",false,"NCT07131696","The Effect of Transcutaneous Vagal Nerve Stimulation (tVNS) on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid Hemorrhage","Inclusion Criteria:\n\n* Provision of signed and dated informed consent\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or Female\n* 18-65 years of age\n* Diagnosed with Fisher grade 3 or 4 aneurysmal subarachnoid hemorrhage\n* Ability to undergo endovascular treatment of aneurysmal subarachnoid hemorrhage\n* For females of reproductive potential: negative pregnancy test at time of treatment.\n* Plan to undergo standard of care treatment and follow-up\n\nExclusion Criteria:\n\n* Medically unfit to undergo endovascular treatment (e.g., Hunt Hess grade 5)\n* Does not provide consent\n* Posterior circulation aneurysmal subarachnoid hemorrhage\n* Initial aneurysm treatment after post bleed day 1","ALL","18 Years","65 Years",{"count":19,"type":20},10,"ESTIMATED","INTERVENTIONAL",[23],"NA","The significance of developing a safe and effective therapy for aneurysmal subarachnoid hemorrhage (aSAH) patients suffering cerebral vasospasm (CVS) cannot be overstated. Vasospasm - a clamping down of normal arteries in the days following rupture - remains incredibly challenging to treat.1,2 Current drugs and minimally invasive surgical therapies are helpful, yet woefully insufficient. Symptomatic cerebral vasospasm afflicts about 30% of aneurysmal subarachnoid hemorrhage patients and nearly half will go on to suffer a stroke, despite aggressive medical care.1-3 The autonomic nervous system is a balance between sympathetic (fight or flight) and parasympathetic (rest and digest) influence with sympathetic overactivity and inflammation shown to play an important role in the development and severity of cerebral vasospasm.4,5,17-20 Prior studies of autonomic nervous system neuromodulation highlight its promise as a promising potential avenue to improve morbidity and mortality from CVS in aSAH.6-15 Despite progress, continued high levels of CVS morbidity and mortality stress the urgent need for exploration of neuromodulation therapy.\n\nIn this proposal, the study team will modulate the autonomic nervous system function in aSAH patients using transcutaneous vagal nerve stimulation (tVNS). tVNS involves placement of a stimulation electrode on the external ear to non-invasively stimulate a branch of the vagal nerve and increase parasympathetic influence. This device has FDA approval for epilepsy and cluster headache.\n\nThe study hypothesis is that neuromodulation of the autonomic nervous system with tVNS (increasing parasympathetic influence) reduces sympathetic overactivity and inflammation in aSAH resulting in decreased morbidity of CVS.",[26,27,28,29],"Aneurysmal Subarachnoid Hemorrhage","Vasospasm, Cerebral","Transcutaneous Vagal Nerve Stimulation (tVNS)","Endovascular Treatment",[31,32,33],"CVS","aSAH","tVNS","RECRUITING","2026-08-07",{"date":37,"type":38},"2026-08-11","ACTUAL",{"date":40,"type":38},"2026-02-06",{"date":42,"type":20},"2029-09",{"name":44,"class":45},"Marshall Holland","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":15,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":46},"100624083","effect-of-vagus-nerve-stimulation-on-pain-intensity-nerve-conduction-studies-and-functional-outcomes-in-diabetic-peripheral-neuropathy-patients-100624083","NCT07405021","Effect of Vagus Nerve Stimulation on Pain Intensity, Nerve Conduction Studies and Functional Outcomes in Diabetic Peripheral Neuropathy Patients","Inclusion Criteria\n\n* Thirty patients diagnosed with diabetic neuropathy of both genders.\n* Age range between 45 and 60 years.\n* Presence of numbness and\u002For pain in the feet with no other identifiable cause.\n* Pain characterized as stabbing, electric shock-like, or burning in nature.\n* Presence of glove-stocking sensory changes and abnormal sensations in the distal lower limbs.\n* Ability to ambulate independently without assistance.\n* Patients under full medical control.\n* Hemoglobin A1c levels ranging from 6.5% to 7%.\n* History of diabetes mellitus for more than 5 years.\n\nExclusion Criteria\n\n* Implantation of cardiac pacemakers or other electrical stimulation devices.\n* Presence of sinus bradycardia, sick sinus syndrome, or other cardiac arrhythmias.\n* Lumbar radiculopathy.\n* Psychiatric or mental disorders or history of seizures.\n* Visual or auditory impairments or tremors affecting balance.\n* Presence of other neuromuscular disorders.\n* Foot deformities or active foot ulcers.\n* History of lower limb surgical operations.","45 Years","60 Years",{"count":56,"type":20},40,[23],"To evaluate the efficacy of vagus nerve stimulation in reducing neuropathic pain, symptom severity, electrophysiological studies and functional outcomes in patients with diabetic peripheral neuropathy.",[28,60],"Diabetic Polyneuropathy","2026-02-09",{"date":63,"type":38},"2026-02-12",{"date":65,"type":38},"2026-01-01",{"date":67,"type":20},"2026-04-01",{"name":69,"class":45},"Cairo University"]